492 related articles for article (PubMed ID: 31949084)
1. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
[TBL] [Abstract][Full Text] [Related]
2. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
[TBL] [Abstract][Full Text] [Related]
3. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
5. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
[TBL] [Abstract][Full Text] [Related]
6. Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes.
Daousi C; Wilding JP; Aditya S; Durham BH; Cleator J; Pinkney JH; Ranganath LR
Clin Endocrinol (Oxf); 2009 Aug; 71(2):195-201. PubMed ID: 19178509
[TBL] [Abstract][Full Text] [Related]
7. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
8. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
Højberg PV; Vilsbøll T; Rabøl R; Knop FK; Bache M; Krarup T; Holst JJ; Madsbad S
Diabetologia; 2009 Feb; 52(2):199-207. PubMed ID: 19037628
[TBL] [Abstract][Full Text] [Related]
9. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
10. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
11. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
[TBL] [Abstract][Full Text] [Related]
12. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
14. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
16. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial.
Heimbürger SMN; Hoe B; Nielsen CN; Bergmann NC; Hartmann B; Holst JJ; Vilsbøll T; Dejgaard TF; Christensen MB; Knop FK
Diabetologia; 2021 Nov; 64(11):2425-2431. PubMed ID: 34405256
[TBL] [Abstract][Full Text] [Related]
17. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
18. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
19. Effect of gender on the acute effects of whey protein ingestion on energy intake, appetite, gastric emptying and gut hormone responses in healthy young adults.
Giezenaar C; Luscombe-Marsh ND; Hutchison AT; Lange K; Hausken T; Jones KL; Horowitz M; Chapman I; Soenen S
Nutr Diabetes; 2018 Jul; 8(1):40. PubMed ID: 30006513
[TBL] [Abstract][Full Text] [Related]
20. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
